We are delighted to welcome Adrian. His experience in commercializing game changing medical technologies will help execute Vortex’s ambitious plans in the rapidly growing liquid biopsy market. Following EMV Capital's trans-Atlantic strategy, Vortex operates out of the Bay Area and in Cambridge, UK
LONDON (PRWEB) June 02, 2021
Vortex Biosciences has developed the VTX-1, a best-in-class instrument that isolates and purifies Circulating Tumor Cells (CTCs) from blood. These cells can then be used for cancer diagnosis and monitoring, research on drug development, cancer research and development of personalized medicine.
Dr Adrian Kinkaid joins Vortex Biosciences on contract, alongside his other roles as CEO of healthcare diagnostic biotech BioFab Ltd and antibody testing biotech Lumabs BV. A specialist in leading early-stage start-ups, Adrian has led several funding rounds for MIP Diagnostics, a synthetic antibody biotech, where he served as CEO for four years until 2019. He has also secured non-dilutive funding for MIP Diagnostics and BioFab via the prestigious SMART Awards.
Prior to this, he was Chief Commercial Officer for Promexus, a protein biotherapeutics company based on Affimer technology, and Strategic Market Development Leader for Abcam, the leading provider of research antibodies. He has a particular passion for improving patient outcomes and game-changing new technologies, especially in the in vitro diagnostics space.
As CEO, Dr Adrian Kinkaid will be overseeing the operations of Vortex Biosciences across its two sites in San Francisco, US and Cambridge, UK. He will be working closely with the board as well as Dr. Ilian Iliev, the Executive Chairman. Adrian will be using his expertise and experience to help Vortex Biosciences commercialize its medical technologies and grow rapidly in the liquid biopsy market.
On his appointment, Dr Adrian Kinkaid said:
“I am delighted to be joining the Vortex Biosciences team. Vortex is in an unrivalled position with outstanding core technology and a best-in-class platform to provide Circulating Timor Cells (CTCs) with remarkable efficiency and purity. More importantly, Vortex’s VTX-1 platform is providing game-changing opportunities for CTC isolation in the liquid biopsy market.”
Vortex Biosciences Executive Chairman and NetScientific PLC CEO Dr. Ilian Iliev commented:
“We are delighted to welcome Adrian to the team at this critical juncture. We trust Adrian’s experience in commercializing game-changing medical technologies will help execute Vortex’s ambitious plans in the rapidly growing liquid biopsy market. Vortex is now based in two of the world’s greatest biotech clusters – the Bay Area and Cambridge, UK – and is therefore well positioned to exploit the rapid growth in the liquid biopsy market on both sides of the Atlantic.”
Adrian has a PhD in Biochemistry from the University of Southampton, centred on novel assay development, and undertook a post-doctoral position with the Institute of Cancer Research, London. His industrial experience started with agrochemical and pharmaceutical discovery where he developed a range of different biochemical and cell-based assays mainly for high throughput screening applications.
Adrian was also a Founding Member of European Laboratory Research and Innovation Group, a not-for-profit organization that holds conferences and events for thought leadership in the life science and drug discovery communities. He served two terms as Chairman, during which time he established the flagship Drug Discovery event, which is now the leading conference of its kind in Europe.
About Vortex Biosciences
Vortex Biosciences provides an automated, label-free, benchtop solution for isolation and purification of Circulating Tumor Cells (CTCs) from a standard 8 ml tube of blood. The VTX-1 instrument rapidly processes the sample through micro vortices to enrich the CTCs and delivers these highly purified cells into a choice of collection formats. These samples containing viable, undamaged CTCs are easily integrated into downstream genomics, protein markers testing, single cell analysis and staining techniques. Vortex Biosciences was spun-out of UCLA, is backed by EMV Capital, a subsidiary of NetScientific PLC, and other private investors, and is dually based in San Francisco, USA and Cambridge, UK.
About EMV Capital
EMV Capital Ltd (EMVC) is a London-based award-winning investor focused on B2B companies in the healthcare, sustainability and industrials sectors. It is a subsidiary of AIM-listed NetScientific PLC. EMVC’s investments in UK, US and Israel cover a range of technologies including robotics and AI, advanced engineering, power electronics and Medtech. EMVC’s model is to develop customized investment strategies for its portfolio companies, combining its network of private investors, institutional VCs investors and Corporate VC funds.
EMV Capital Limited is an appointed representative of Sapphire Capital Limited, which is authorised and regulated by the Financial Conduct Authority.
For more information, please visit https://www.vortexbiosciences.com
About NetScientific PLC
AIM-listed NetScientific Plc is a life sciences and sustainability technology investment and commercialisation Group, leveraging trans-Atlantic relationships and global opportunities to deliver shareholder value. For more information, please visit the website at https://netscientific.net/
EMV Capital Ltd | http://www.emvcapital.com
Dr. Ilian Iliev, Managing Director
+44 (0)203 761 6138
Vortex Biosciences, Inc | http://www.vortexbiosciences.com
Dr. Adrian Kinkaid, CEO